Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Adavosertib

(AZD1775)

Phase 2Small molecule

AZD1775 is an experimental cancer drug being tested to treat various types of cancer by targeting a protein that helps cancer cells survive and divide.[1] Adavosertib is currently being investigated across 7 indications[3], with its most advanced program in Phase 2.[1]

Adavosertib is one of 61 small molecule programs targeting Uterine Cancer. It is currently in Phase 2.

7

Indications

29

Total Trials

11

Active Trials

60

Competitors

Pipeline

Status by Indication[3][1]

Indication

Uterine CancerActive, not recruiting

Pediatric CancerRecruiting

Advanced LymphomaActive, not recruiting

Recurrent Fallopian Tube CarcinomaActive, not recruiting

Clear Cell Renal Cell CarcinomaActive, not recruiting

Clinical Stage III Esophageal Adenocarcinoma AJCC V8Active, not recruiting

Advanced Fallopian Tube CarcinomaActive, not recruiting

Uterine CancerPhase 2

Active, not recruiting

Pediatric CancerPreclinical

Recruiting

Advanced LymphomaPhase 2

Active, not recruiting

Recurrent Fallopian Tube CarcinomaPhase 2

Active, not recruiting

Clear Cell Renal Cell CarcinomaPhase 2

Active, not recruiting

Clinical Stage III Esophageal Adenocarcinoma AJCC V8Phase 1

Active, not recruiting

Advanced Fallopian Tube CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

28 competitors in Pediatric Cancer

#DrugCompanyPhaseTrials

Adavosertib

Trisenox

Cytosar

Bavencio

Zanzalintinib

Kisqali

Afinitor

Lynparza

Camptosar

Opdivo

Bristol-Myers Squibb

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Muscle-Invasive Bladder Cancer

NCT02546661

Phase 1Active, not recruiting

Clinical Stage III Esophageal Adenocarcinoma AJCC V8

NCT04460937

Phase 2Active, not recruiting

Advanced Lymphoma

NCT04439227

Phase 1Active, not recruiting

Advanced Fallopian Tube Carcinoma

NCT02659241

Phase 1Active, not recruiting

Advanced Malignant Solid Neoplasm

NCT04197713

Phase 2Active, not recruiting

Recurrent Fallopian Tube Carcinoma

NCT03579316

Clinical

Trials by Indication[1]

Lung Cancer4 trials

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

Terminated· AstraZeneca logo

AstraZeneca·Phase 2·NCT02087176·48 enrolled

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT02513563·42 enrolled

Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer

Terminated· AstraZeneca logo

AstraZeneca·Phase 2·NCT02087241·22 enrolled

Show 1 more trial

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT02937818·72 enrolled

Small Cell Lung Cancer2 trials

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients

Completed·SSamsung Medical Center·Phase 2·NCT02593019·24 enrolled

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation

Terminated·SSamsung Medical Center·Phase 2·NCT02688907·7 enrolled

Advanced Lymphoma2 trials

MATCH Treatment Subprotocol Z1I: Phase II Study of AZD1775 in Patients With Tumors Containing BRCA1 and BRCA2 Mutations

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04439227·33 enrolled

Molecular Analysis for Therapy Choice (MATCH)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02465060·6,452 enrolled

Metastatic Colorectal Cancer1 trial

Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

Completed·NNYU Langone Health·Phase 1·NCT02906059·7 enrolled

Gastric Adenocarcinoma1 trial

Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy

Completed·SSamsung Medical Center·Phase 2·NCT02448329·26 enrolled

19 more indications

Advanced Solid Tumours1 trial

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02617277·56 enrolled

Head and Neck Cancer1 trial

WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer

Completed·UUniversity of Birmingham·Phase 1·NCT03028766·9 enrolled

Breast Cancer1 trial

CISPLATIN + AZD-1775 In Breast Cancer

Completed·—·Phase 2·NCT03012477·34 enrolled

Solid Tumours1 trial

Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02341456·19 enrolled

Refractory Solid Tumors1 trial

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02511795·128 enrolled

Recurrent1 trial

A Phase 0 Study of AZD1775 in Recurrent GBM Patients

Completed·SSt. Joseph's Hospital and Medical Center, Phoenix·Phase 1·NCT02207010·20 enrolled

Cisplatin1 trial

Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT02585973·12 enrolled

Advanced or Metastatic Solid Tumour1 trial

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02610075·62 enrolled

Pancreatic Cancer1 trial

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02194829·8 enrolled

Clear Cell Renal Cell Carcinoma1 trial

A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03284385·18 enrolled

Advanced Fallopian Tube Carcinoma1 trial

A Pilot Study of Wee1 Inhibition Induction Prior to Tumor Reductive Surgery in Ovarian Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT02659241·38 enrolled

Muscle-Invasive Bladder Cancer1 trial

An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY).

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT02546661·117 enrolled

Advanced Malignant Solid Neoplasm1 trial

Phase I Sequential Trial of Agents Against DNA Repair (STAR)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04197713·13 enrolled

Uterine Cancer1 trial

A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Active, not recruiting·DDana-Farber Cancer Institute·Phase 2·NCT03668340·49 enrolled

Ovarian Brenner Tumor1 trial

A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02101775·124 enrolled

Clinical Stage III Esophageal Adenocarcinoma AJCC v81 trial

A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) With Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04460937·4 enrolled

Recurrent Fallopian Tube Carcinoma1 trial

EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03579316·96 enrolled

Pediatric Cancer1 trial

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Preclinical·NCT02813135·472 enrolled

Unspecified1 trial

OLAParib COmbinations

Terminated·JJoseph Paul Eder·Phase 2·NCT02576444·67 enrolled

Sources

References

[1]
ClinicalTrials.gov — 29 trial records for AZD1775. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD1775 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD1775. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

Related News